Featuring perspectives from Dr Samuel J Klempner and Dr Stephen "Fred" Divers, moderated by Dr Divers, including the following topics:

• Introduction (0:00)
• First-Line Treatment of Metastatic Gastroesophageal Cancer (1:48)
• Management of HER2-Positive Gastroesophageal Cancer (25:11)
• Neoadjuvant Therapy for Gastroesophageal Cancer (45:13)

Note to listeners: Subsequent to the recording of this symposium, the FDA approved zanidatamab in combination with chemotherapy with and without tislelizumab for HER2-positive gastric, gastroesophageal junction, or esophageal adenocarcinoma based on results from the Phase III HERIZON-GEA-01 trial.

CME information and select publications

Featuring perspectives from Ms Caroline Kuhlman, Dr Eileen M O'Reilly, Dr Philip A Philip and Ms Amanda K Wagner, moderated by Dr O'Reilly, including the following topics:

• Introduction (0:00)
• Clinical Presentation and Prognosis of Pancreatic Adenocarcinoma (PAD) (3:29)
• Recent Advances in Up-Front Treatment for Metastatic PAD (15:47)
• Selection and Sequencing of Therapy for Relapsed/Refractory Metastatic PAD (39:58)
• Novel Strategies Targeting RAS Mutations in Advanced PAD (48:20)
• Utility of Tumor Treating Fields in PAD Management (1:13:58)

CME information and select publications

Featuring perspectives from Dr David H Ilson and Dr Kohei Shitara, including the following topics:

• Introduction (0:00)
• Biomarker Evaluation in Localized and Metastatic Disease (1:49)
• Role of Immune Checkpoint Inhibitors in the Management of Gastroesophageal Cancers — Dr Ilson (7:37)
• Other Available Therapeutic Approaches — Dr Shitara (33:22)

CME information and select publications